Xenon Pharmaceuticals (XENE) Tops Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Xenon Pharmaceuticals (XENE) Tops Q4 EPS by 1c

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

February 27, 2025 4:01 PM EST

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch

First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year

Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year

Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025

Neurocrine collaboration achieves milestone with initiation of Phase 1 study of Nav1.2/Nav1.6 inhibitor

Conference call at 4:30 pm ET today

VANCOUVER,... More